The prevalence and cost of diabetes in metropolitan France: what trends between 1998 and 2000?*.
OBJECTIVE
Our aim was to update available data concerning the prevalence and cost of diabetes in metropolitan France.


METHODS
We performed a retrospective study using patient reimbursement data from all the 128 local health offices (CPAM) in metropolitan France. We selected patients who received reimbursements for an oral hypoglycemic agent or insulin. Thus, 704,423 patients were studied by using 1998 data and 1,145,603 patients were studied by using data from 2000. The expenditures studied represented the total amount reimbursed by national health insurance to diabetic patients. The cost differential which could be attributed to diabetes was calculated by determining the difference between costs generated by diabetic patients to those generated by the rest of the population of the same age.


RESULTS
Between 1998 and 2000, the prevalence of diabetes treated in the population of affiliates covered by the general scheme increased from 2.78% to 2.96%. The total amount paid by the general scheme for care to diabetic patients (related to diabetes or not) was 5.710 billion euros in 2000 compared to 4.862 billion euros in 1998. The amount which can be attributed to diabetes alone can be estimated to be 2.414 billion euros in 2000 compared to 2.021 billion euros in 1998. After considering the impact of the increase in the number of treated diabetics, a modification in the modalities of medical care probably accounts for 183 million euros of the cost increase. Medical equipment (self blood glucose monitoring devices, reagent strips, finger lancets...) accounts for 39.3% (72 million euros) of this cost differential, medications account for 34.4% (63 million euros) and nursing care 16.9% (31 million euros). There was no change in the cost of diabetes with relation to expenses for medical consultations.
Ricordeau
Ph
P
Direction du Service médical de l'Assurance maladie, CNAMTS, Paris, France. philippe.ricourdeau@cnamts.fr
Weill
A
A
Vallier
N
N
Bourrel
R
R
Schwartz
D
D
Guilhot
J
J
Fender
P
P
Allemand
H
H
D003365:Costs and Cost Analysis; D003920:Diabetes Mellitus / Q000191:economics* / Q000453:epidemiology* / Q000628:therapy; D011307:Drug Prescriptions / Q000191:economics; D005602:France / Q000453:epidemiology; D006801:Humans; D007004:Hypoglycemic Agents / Q000191:economics / Q000627:therapeutic use; D007328:Insulin / Q000191:economics / Q000627:therapeutic use; D010045:Outpatients; D015995:Prevalence; D012051:Reimbursement Mechanisms; D012189:Retrospective Studies; D014505:Urban Population
D007004:Hypoglycemic Agents; D007328:Insulin